Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Arvinas Operations Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 4 distinct examiners, resulting in a distributed workload where each examiner manages 1 pending action. The portfolio's activity is situated within 3 distinct art units, indicating that the company's current patent applications are being reviewed by a small group of related examination units.
SEAMAN, D MARGARET M is the busiest examiner for the company, holding 1 pending office action. With 4 pending office actions spread across 3 distinct art units, the prosecution strategy involves addressing the specific requirements of a few different technical niches within the pharmaceutical sector. This distribution ensures that no examiner or art unit dominates the current pending inventory. The presence of 4 distinct examiners for the actions means that the company's success is tied to the individual perspectives of several different officials. Practitioners must coordinate their efforts across the 3 distinct art units to maintain consistency in the company's broader biotechnology claims while satisfying the unique demands of each examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.5% | +8.0% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| RICCI, CRAIG D | 1 | 53.5% | +52.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18834785 | DGK TARGETING COMPOUNDS AND USES THEREOF | SEAMAN, D MARGARET M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18456718 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | RICCI, CRAIG D | 99d overdue |
| 18772066 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | MOU, LIYUAN | — |
| 18669105 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | KIFLE, BRUCK | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1624 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18834785 | DGK TARGETING COMPOUNDS AND USES THEREOF | SEAMAN, D MARGARET M | — | §102§112 | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18772066 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | MOU, LIYUAN | 1628 | §103§112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18669105 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | KIFLE, BRUCK | 1624 | §102§103§112DP | Non-Final OA | — | Pending | May 20, 2024 |
| 18456718 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | RICCI, CRAIG D | 1611 | §103 | Final Rejection | 99d overdue | Pending | Aug 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial